Chugai Pharmaceutical Co., Ltd.
4519
Hisse Senetlerindeki Sıralama
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Hisse Fiyatı
$41.60
Piyasa Değeri
$68.46B
Değişim (1 gün)
0.94%
Değişim (1 yıl)
-12.56%
Ülke
JP
Ticaret Chugai Pharmaceutical Co., Ltd. (4519)
Kategori
Healthcare
Chugai Pharmaceutical Co., Ltd. (4519) için kazanç
2026 itibarıyla kazanç TTM: 0
Chugai Pharmaceutical Co., Ltd. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Chugai Pharmaceutical Co., Ltd. için kazanç geçmişi 2003 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2025 | $3.81B | 10.18% |
| 2024 | $3.46B | 9.91% |
| 2023 | $3.15B | -22.32% |
| 2022 | $4.05B | 11.19% |
| 2021 | $3.64B | 26.14% |
| 2020 | $2.89B | 51.00% |
| 2019 | $1.91B | 72.67% |
| 2018 | $1.11B | 28.63% |
| 2017 | $861.20M | 35.29% |
| 2016 | $636.58M | -12.20% |
| 2015 | $725.04M | 14.00% |
| 2014 | $635.98M | -12.96% |
| 2013 | $730.71M | -13.05% |
| 2012 | $840.36M | 13.52% |
| 2011 | $740.25M | -8.49% |
| 2010 | $808.92M | -16.02% |
| 2009 | $963.18M | 38.51% |
| 2008 | $695.38M | 17.04% |
| 2007 | $594.11M | 12.26% |
| 2006 | $529.22M | -27.64% |
| 2005 | $731.36M | 30.51% |
| 2004 | $560.37M | 21.93% |
| 2003 | $459.59M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
